Indication

T-cell lymphoblastic lymphoma

T-cell lymphoblastic lymphoma is an aggressive precursor lymphoid neoplasm characterized by the malignant proliferation of immature T-cell lymphoblasts. Read more about T-cell lymphoblastic lymphoma

13 drugs 13 manufacturers

Advertisement

Drugs that treat it

Common T-cell lymphoblastic lymphoma therapies.

Showing 10–13 of 13 drugs

NELARABINE

PURINE ANALOGUES·T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
X-GEN PHARMACEU

NELARABINE

PURINE ANALOGUES·T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
ZYDUS USA-NOVAP

NELARABINE

PURINE ANALOGUES·T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA·+1
Amneal Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with T-cell lymphoblastic lymphoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About T-cell lymphoblastic lymphoma.

T-cell lymphoblastic lymphoma is an aggressive precursor lymphoid neoplasm characterized by the malignant proliferation of immature T-cell lymphoblasts.

The disease most commonly affects children, adolescents, and young adults, exhibiting a pronounced male predominance.

Biologically continuous with T-cell acute lymphoblastic leukemia, it is distinguished clinically by primary nodal or extranodal mass lesions—classically an anterior mediastinal mass involving the thymus and regional lymph nodes—with less than 25% blast involvement in the bone marrow.

Pathophysiologically, the neoplastic cells express immature T-lineage markers such as terminal deoxynucleotidyl transferase (TdT) and CD3, frequently accompanied by recurrent oncogenic drivers including NOTCH1 mutations.

Personalize your experience

Follow T-cell lymphoblastic lymphoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it